HomeAI · summaries
Storia in 4 fonti
Datroway nabs FDA approval for immunotherapy-ineligible triple-negative breast cancer
The FDA approved datopotamab deruxtecan-dlnk as the first TROP2-directed antibody drug conjugate for first-line treatment of unresectable or metastatic triple-negative breast cancer in patients ineligible for PD-1/PD-L1 inhibitor therapy.The agency granted priority review and approved datopotamab deruxtecan (Datroway; AstraZeneca, Daiichi Sankyo) based on results from the phase 3 TROPION-Breast02
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Datroway nabs FDA approval for immunotherapy-ineligible triple-negative breast cancer
The FDA approved datopotamab deruxtecan-dlnk as the first TROP2-directed antibody drug conjugate for first-line treatment of unresectable or metastatic triple-negative breast…
- ·
morningstar.com
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple…
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not…
- ·
endpoints.news
FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval
The FDA has approved the TROP2-directed ADC Datroway as a first-line option for triple-negative breast cancer, giving Daiichi Sankyo and AstraZeneca a leg up over their competitor…
- ·
fiercepharma.com
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is…